Evidence map›Paper›PMID 39605676›Full record

ArticlebioRxiv : the preprint server for biology2024

Single-cell epigenetic profiling reveals an interferon response-high program associated with

Sabrina Y Camp, Meng Xiao He, Michael S Cuoco, Eddy Saad, Erica Pimenta, Kevin Meli, Ziad Bakouny, Chris Labaki, Breanna M Titchen, Yun Jee Kang and 14 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sabrina Y CampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9695-5527
Meng Xiao HeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-8622-7470
Michael S CuocoBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.ORCID 0000-0003-2163-5120
Eddy SaadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0001-8700-9312
Erica PimentaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9684-6486
Kevin MeliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9579-3829
Ziad BakounyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0003-1906-5704
Chris LabakiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9584-8455
Breanna M TitchenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-1569-0513
Yun Jee KangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jack HorstDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0009-0001-5854-1825
Rachel TrowbridgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0003-4059-2031
Erin ShannonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Karla HelvieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-3514-0332
Aaron R ThornerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9160-7881
Sébastien VigneauDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9091-2067
Angie MayorgaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jahnavi KodaliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Hannah LachmayrDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0003-1850-9019
Meredith BemusDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-4451-2046
Toni ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-9201-3217
Kevin BiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-6794-1804
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-0201-4444

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4M
MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
Molecular Origins and Evolution to Chemoresistance in Germ Cell TumorsR37CA222574 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2024
$3.2M
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney CancerR01CA278980 · NCI · DANA-FARBER CANCER INST · PI Eliezer M Van Allen · 2024 to 2026
$2.1M
Molecular origins and evolution to treatment resistance in genitourinary cancersR50CA265182 · NCI · DANA-FARBER CANCER INST · PI Jihye Park · 2022 to 2026
$1.7M
NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA278980NCI NIH HHS R37 CA222574NCI NIH HHS R50 CA265182NIGMS NIH HHS T32 GM008313
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is characterized by recurrent somatic mutations in epigenetic regulators, which stratify patients into clinically significant subgroups with distinct prognoses and treatment responses. However, the cell type-specific epigenetic landscape of RCC-broadly and in the context of these mutations-is incompletely understood. To investigate these open questions, we integrated single nucleus ATAC sequencing data from RCC tumors across four independent cohorts. In clear cell RCC tumors, we identified four shared malignant epigenetic programs related to angiogenesis, proximal tubule-like features, interferon (IFN) signaling, and one that lacked distinct genomic regions with increased accessibility. Among the mutated epigenetic regulators,

Identifiers

PMID39605676
PMCPMC11601305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.